Wednesday, July 8, 2026

Drug profile · INN

danaparoid sodium

danaparoid sodium (ORGARAN) is a antithrombin-iii activator. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — danaparoid sodium
US status
approved
Class
Route
INJECTION
Patents
0
Programs
0
Data quality
0.84

Quick answer

danaparoid sodium (ORGARAN) is a antithrombin-iii activator. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN danaparoid sodium
Brand ORGARAN
Mechanism Antithrombin-III activator
Target Antithrombin-III
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Antithrombin-III activator

Primary target: Antithrombin-III

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. enoxaparin sodium Blood and blood forming organs (B01)
  2. fondaparinux sodium Blood and blood forming organs (B01)
  3. heparin sodium Antithrombin-III activator
  4. ardeparin sodium Antithrombin-III activator
  5. dalteparin sodium Antithrombin-III activator
  6. heparin calcium Antithrombin-III activator

Frequently asked questions

What is danaparoid sodium?

danaparoid sodium (ORGARAN) is a antithrombin-iii activator. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for danaparoid sodium?

ORGARAN is a marketed brand name for danaparoid sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of danaparoid sodium?

danaparoid sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.